Sick Economics

Searching For Healthy Profits In The Stock Market


Hot Biotech IPOs 2019

These three small companies are dreaming big. Each aims to make a major impact in a different disease state. If you have an appetite for innovation and a tolerance for risk, these upcoming 2019 biotech IPO’s could appeal to you…



Stoke describes its mission as the following:

 Stoke’s proprietary TANGO technology platform can be used to treat a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies.

Using our proprietary TANGO platform, we aim to increase protein production from the remaining healthy copy of a gene and to restore the protein to near normal levels, thereby slowing or stopping disease progression.”

In other words, Stoke aims to help sick bodies make more of proteins that are lacking. The TANGO technology is their entry into the super hot world or Messenger RNA, a realm where competitors such as Moderna ($MRNA) have already had early success.

The first disease they are targeting is Dravet’s Syndrome, a catastrophic form of epilepsy that occurs in one out of 21,000 babies. Dravet’s is considered an ideal starting place for the TANGO technology because it is caused by just one broken gene, and the rarity of the disease means competition in the niche will be limited.

The company lost $12.5 million with $0 in revenue in 2018. It is aiming for a roughly $430 million dollars valuation, with an initial share price range of $14-$16.


 Personalis offers a proprietary platform for cancer research, especially in the immunotherapy development field. The company plans to partner with active oncology practitioners and researchers in the following three niches: ImmunoOncology treatment, Oncology research, and Oncology Diagnostics.  The company boasts that it can provide the most comprehensive genomic analysis of a tumor from a single sample.

Personalis lately announced a partnership with the Parker Institute for Immunotherapy by which the Institute will utilize the ImmunoIDNext technology to research relevant biomarkers for cancer immunotherapy. The company booked $48 million in sales for the 12 months ended March 31, 2019. If shares price in the expected $14-$16 range, Personalis will start its life as a public company with a market value of about $430 million.



Prevail also seeks to pioneer cures through gene therapy. Specifically, Prevail is focusing on Parkinson’s disease and other neurodegenerative diseases. Prevail is partnered with Regenex Bio and the non-profit Silverstein Foundation.

The company’s core hypothesis is that restoring healthy lysosomal function in the cells of a patient’s central nervous system could stop the progression of neurodegenerative disease.

On June 4th, Prevail received permission from the FDA to move forward with phase 1& phase 2 testing of it’s lead Parkinson’s candidate, PR-001. The first patients should be dosed by the end of 2019.  

The company plans to raise $125 million dollars through its IPO, with shares pricing in the range of $16 to $18. If shares price in the middle of this range, Prevail will be worth approximately $670million immediately after the shares hit the market.


Barbeques, swimming parties, and blazing biotech IPO’s.  Enjoy your long, hot summer…..


Subscribe To The Rx Newsletter

sick economics

You understand that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. You further understand that none of the bloggers, information providers, app providers, or their affiliates are advising you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent that any of the content published on the Site may be deemed to be investment advice or recommendations in connection with a particular security, such information is impersonal and not tailored to the investment needs of any specific person. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Site will not contain a list or description of relevant risk factors.

The Site is not intended to provide tax, legal, insurance or investment advice, and nothing on the Site should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Sick Economics or any third party. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should consult an attorney or tax professional regarding your specific legal or tax situation.